The global hemophilia market is anticipated to reach US$13.86 billion 2024, growing at a CAGR of 5.61% during the period spanning 2020-2024. The growth in the market has been driven by factors like increasing healthcare expenditure and surging identified hemophilia patient volume. The market is expected to face certain challenges such as high cost of treatment and reluctance to switch to newer therapies. To overcome these challenges, the market would witness some key trends like development of novel hemophilia treatments and rising popularity of gene therapy.
The global hemophilia market by treatment regimen can be segmented as follows: prophylaxis and on-demand. In 2019, the higher share was held by prophylaxis segment, followed by on-demand segment. The global hemophilia market by type can be segmented into the following: hemophilia A and hemophilia B, where hemophilia A held a larger share of the market in 2019. The global hemophilia market by therapy can be segmented as follows: replacement therapy and ITI therapy. The dominant share of the market in 2019 was held by replacement therapy segment. The global hemophilia market by region can be segmented into the following regions: North America, Europe and Asia Pacific.
In 2019, the dominant share of the market was held by North America, followed by Europe and Asia Pacific. The factors like rising prevalence of hemophilia, growing knowledge amongst individuals regarding different treatment methods and surging inclination towards prophylaxis treatment contributed towards growth in the North American market.
Scope of the report:
The report provides a comprehensive analysis of the global hemophilia market, segmented into hemophilia A and hemophilia B.
The major regional markets North America, Europe and Asia Pacific with country analysis of the US have been analyzed.
The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Bayer Group, Sanofi S.A., Takeda Pharmaceutical Company, Novo Nordisk and CSL Limited) are also presented in detail.
Key Target Audience:
Hemophilia Drugs Manufacturers
End Users (Hospital, Medical centers, Clinical Institutes)
Healthcare Consulting Firms
Government Bodies & Regulating Authorities